149 related articles for article (PubMed ID: 17719727)
1. Safety, tolerability and subject-rated effects of acute intranasal cocaine administration during atomoxetine maintenance.
Stoops WW; Blackburn JW; Hudson DA; Hays LR; Rush CR
Drug Alcohol Depend; 2008 Jan; 92(1-3):282-5. PubMed ID: 17719727
[TBL] [Abstract][Full Text] [Related]
2. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance.
Stoops WW; Lile JA; Lofwall MR; Rush CR
Am J Drug Alcohol Abuse; 2007; 33(6):769-76. PubMed ID: 17994473
[TBL] [Abstract][Full Text] [Related]
3. Cocaine effects during D-amphetamine maintenance: a human laboratory analysis of safety, tolerability and efficacy.
Rush CR; Stoops WW; Hays LR
Drug Alcohol Depend; 2009 Jan; 99(1-3):261-71. PubMed ID: 18926645
[TBL] [Abstract][Full Text] [Related]
4. Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants.
Cantilena L; Kahn R; Duncan CC; Li SH; Anderson A; Elkashef A
J Addict Med; 2012 Dec; 6(4):265-73. PubMed ID: 22987022
[TBL] [Abstract][Full Text] [Related]
5. The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period.
Lile JA; Stoops WW; Hays LR; Rush CR
Am J Drug Alcohol Abuse; 2008; 34(6):721-9. PubMed ID: 18855244
[TBL] [Abstract][Full Text] [Related]
6. Physiological and subjective effects of acute intranasal methamphetamine during atomoxetine maintenance.
Rush CR; Stoops WW; Lile JA; Glaser PE; Hays LR
Pharmacol Biochem Behav; 2011 Nov; 100(1):40-7. PubMed ID: 21802442
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of intranasal cocaine during phendimetrazine maintenance.
Stoops WW; Strickland JC; Hays LR; Rayapati AO; Lile JA; Rush CR
Psychopharmacology (Berl); 2016 Jun; 233(11):2055-2063. PubMed ID: 26932737
[TBL] [Abstract][Full Text] [Related]
8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
9. Cocaine choice in humans during D-amphetamine maintenance.
Rush CR; Stoops WW; Sevak RJ; Hays LR
J Clin Psychopharmacol; 2010 Apr; 30(2):152-9. PubMed ID: 20520288
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of atomoxetine in treatment of attention deficit hyperactivity disorder in adult patients: an integrated analysis of 15 clinical trials.
Camporeale A; Porsdal V; De Bruyckere K; Tanaka Y; Upadhyaya H; Deix C; Deberdt W
J Psychopharmacol; 2015 Jan; 29(1):3-14. PubMed ID: 25424623
[TBL] [Abstract][Full Text] [Related]
11. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.
Lile JA; Stoops WW; Durell TM; Glaser PE; Rush CR
Exp Clin Psychopharmacol; 2006 May; 14(2):136-47. PubMed ID: 16756417
[TBL] [Abstract][Full Text] [Related]
12. Atomoxetine in abstinent cocaine users: Cognitive, subjective and cardiovascular effects.
DeVito EE; Herman AI; Konkus NS; Zhang H; Sofuoglu M
Pharmacol Biochem Behav; 2017 Aug; 159():55-61. PubMed ID: 28716656
[TBL] [Abstract][Full Text] [Related]
13. A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and efficacy of mixed amphetamine salts extended release and atomoxetine in school-age girls with attention-deficit/hyperactivity disorder.
Biederman J; Wigal SB; Spencer TJ; McGough JJ; Mays DA
Clin Ther; 2006 Feb; 28(2):280-93. PubMed ID: 16678649
[TBL] [Abstract][Full Text] [Related]
14. Subchronic administration of atomoxetine causes an enduring reduction in context-induced relapse to cocaine seeking without affecting impulsive decision making.
Broos N; Loonstra R; van Mourik Y; Schetters D; Schoffelmeer AN; Pattij T; De Vries TJ
Addict Biol; 2015 Jul; 20(4):714-23. PubMed ID: 25056833
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine does not alter cocaine use in cocaine dependent individuals: double blind randomized trial.
Walsh SL; Middleton LS; Wong CJ; Nuzzo PA; Campbell CL; Rush CR; Lofwall MR
Drug Alcohol Depend; 2013 Jun; 130(1-3):150-7. PubMed ID: 23200303
[TBL] [Abstract][Full Text] [Related]
16. Intranasal cocaine in humans: acute tolerance, cardiovascular and subjective effects.
Foltin RW; Haney M
Pharmacol Biochem Behav; 2004 May; 78(1):93-101. PubMed ID: 15159138
[TBL] [Abstract][Full Text] [Related]
17. Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers.
Oliveto A; McCance-Katz FE; Singha A; Petrakis I; Hameedi F; Kosten TR
Drug Alcohol Depend; 2001 Jul; 63(2):155-67. PubMed ID: 11376920
[TBL] [Abstract][Full Text] [Related]
18. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine effects on attentional bias to drug-related cues in cocaine dependent individuals.
Passamonti L; Luijten M; Ziauddeen H; Coyle-Gilchrist ITS; Rittman T; Brain SAE; Regenthal R; Franken IHA; Sahakian BJ; Bullmore ET; Robbins TW; Ersche KD
Psychopharmacology (Berl); 2017 Aug; 234(15):2289-2297. PubMed ID: 28551713
[TBL] [Abstract][Full Text] [Related]
20. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans.
Lile JA; Stoops WW; Allen TS; Glaser PE; Hays LR; Rush CR
Psychopharmacology (Berl); 2004 Feb; 171(4):441-9. PubMed ID: 14504683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
